The importance of anti-insulin antibody in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion or multiple daily insulin injections therapy

Basit Öğe Kaydı
dc.contributor.authorSahin, S. B.
dc.contributor.authorCetinkalp, S.
dc.contributor.authorOzgen, A. G.
dc.contributor.authorSaygili, F.
dc.contributor.authorYilmaz, C.
dc.date.accessioned2019-10-27T21:28:55Z
dc.date.available2019-10-27T21:28:55Z
dc.date.issued2010
dc.departmentEge Üniversitesien_US
dc.description.abstractTo investigate the influence of two insulin administration modalities, continuous subcutaneous insulin infusion (CSII) and multiple daily insulin injections (MDI) therapy with insulin analogues, on the development of insulin antibodies (IAs) in patients with type 1 diabetes mellitus and to assess the impact of IAs on glucose control and hypoglycaemia. 96 patients with type 1 diabetes mellitus treated with CSII (n = 48) or MDI (n = 48) were included in the study. Age, duration of diabetes, A1c, preprandial and postprandial blood glucose and hypoglycaemic events were compared between IA positive and negative patients. IA levels were higher in the CSII group (% 24.6 +/- A 14.2) than the MDI group (% 13.2 +/- A 9.9). Duration of diabetes and age were not associated with IA positiveness. While A1c, preprandial blood glucose and the frequency of hypoglycaemic events were similar in two groups, postprandial blood glucose was lower in IA positive group (P = 0.03). Patients with type 1 diabetes mellitus treated with CSII with insulin analogues had higher IA levels when compared to MDI therapy. However, the development of IAs did not impair the glycaemic control.en_US
dc.identifier.doi10.1007/s00592-010-0221-5en_US
dc.identifier.endpage330en_US
dc.identifier.issn0940-5429
dc.identifier.issn1432-5233
dc.identifier.issue4en_US
dc.identifier.pmid20842389en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage325en_US
dc.identifier.urihttps://doi.org/10.1007/s00592-010-0221-5
dc.identifier.urihttps://hdl.handle.net/11454/45235
dc.identifier.volume47en_US
dc.identifier.wosWOS:000283584200007en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer-Verlag Italia Srlen_US
dc.relation.ispartofActa Diabetologicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnti-insulin antibodyen_US
dc.subjectType 1 diabetes Continuous subcutaneous insulin infusionen_US
dc.subjectMultiple daily insulin injectionsen_US
dc.titleThe importance of anti-insulin antibody in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion or multiple daily insulin injections therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu